Maximal cytoreductive effort in epithelial ovarian cancer surgery

被引:110
|
作者
Shih, Karin K. [1 ]
Chi, Dennis S. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
关键词
Ovarian cancer; Cytoreduction; PRIMARY PERITONEAL CANCER; SECONDARY CYTOREDUCTION; SURGICAL CYTOREDUCTION; RESIDUAL DISEASE; FALLOPIAN-TUBE; RECTOSIGMOID COLECTOMY; TERTIARY CYTOREDUCTION; 2ND-LOOK LAPAROTOMY; SELECTION CRITERIA; BOWEL RESECTION;
D O I
10.3802/jgo.2010.21.2.75
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The surgical management of advanced epithelial ovarian cancer involves cytoreduction, or removal of grossly-evident tumor. Residual disease after surgical cytoreduction of ovarian cancer has been shown to be strongly associated with survival. The goal of surgery is "optimal" surgical cytoreduction, which is generally defined as residual disease of 1 cm or less. However, the designation of "optimal" surgical cytoreduction has evolved to include maximal surgical effort and no gross residual disease. In order to achieve this, more aggressive surgical procedures such as rectosigmoidectomy, diaphragm peritonectomy, partial liver resection, and video-assisted thoracic surgery are reported and increasingly utilized in the surgical management of advanced ovarian cancer. The role of maximal surgical effort also extends to the recurrent setting where the goal of surgery should be complete cytoreduction. Patient selection is important in identifying appropriate candidates for surgical cytoreduction in the recurrent setting. The purpose of this article is to review the role of maximum surgical effort in primary and recurrent ovarian cancer.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 50 条
  • [21] Evaluation of second cytoreductive surgery in the treatment of epithelial ovarian cancer
    孙廷慰
    酆豫增
    中华医学杂志(英文版), 1998, (03) : 80 - 82
  • [22] SECONDARY CYTOREDUCTIVE SURGERY FOR RECURRENT EPITHELIAL OVARIAN-CANCER
    MORRIS, M
    GERSHENSON, DM
    WHARTON, JT
    COPELAND, LJ
    EDWARDS, CL
    STRINGER, CA
    GYNECOLOGIC ONCOLOGY, 1989, 34 (03) : 334 - 338
  • [23] Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer
    Bacalbasa, Nicolae
    Balescu, Irina
    Dima, Simona
    Brasoveanu, Vladislav
    Popescu, Irinel
    ANTICANCER RESEARCH, 2015, 35 (09) : 5097 - 5101
  • [24] Does maximal effort cytoreductive surgery after 6-cycles of chemotherapy play a role in the management of advanced ovarian cancer?
    Cassar, Viktor
    Rundle, Stuart
    Rongali, Velangali Bhavya Swetha
    Korompelis, Porfyrios
    Ang, Christine
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2024, 310 (06) : 3057 - 3065
  • [25] Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
    Fotopoulou, C.
    Savvatis, K.
    Kosian, P.
    Braicu, I. E.
    Papanikolaou, G.
    Pietzner, K.
    Schmidt, S-C
    Sehouli, J.
    BRITISH JOURNAL OF CANCER, 2013, 108 (01) : 32 - 38
  • [26] Quaternary cytoreductive surgery in ovarian cancer: does surgical effort still matter?
    C Fotopoulou
    K Savvatis
    P Kosian
    I E Braicu
    G Papanikolaou
    K Pietzner
    S-C Schmidt
    J Sehouli
    British Journal of Cancer, 2013, 108 : 32 - 38
  • [27] Association of Diaphragmatic Surgery as Part of Cytoreductive Effort in Advanced Stage Ovarian Cancer
    Bacalbasa, Nicolae
    Balescu, Irina
    Balalau, Cristian
    Ionescu, Olivia
    Stoica, Claudia
    IN VIVO, 2018, 32 (02): : 431 - 436
  • [28] PROGNOSTIC FACTORS FOLLOWING CYTOREDUCTIVE SURGERY FOR ADVANCED EPITHELIAL OVARIAN CANCER
    Martinez Lamela, Ester
    Molero Vilchez, Jesus
    Santiago Gomez, Angela
    Suarez Aguado, Judith
    Exposito Lucena, Yolanda
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A267 - A268
  • [29] SPLENECTOMY AS PRIMARY CYTOREDUCTIVE SURGERY IN ADVANCED STAGE EPITHELIAL OVARIAN CANCER
    Akilli, H.
    Karakas, L. Aksoy
    Nihan, H.
    Ayhan, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A429 - A430
  • [30] Cytoreductive surgery in ovarian cancer
    Lyngstadaas, A
    Hagen, B
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 69 - 70